Navigation Links
Ventus Medical Announces PROVENT(R) Sleep Apnea Therapy Recognized by The Wall Street Journal 2009 Technology Innovation Awards
Date:9/21/2009

BELMONT, Calif., Sept. 21 /PRNewswire/ -- Ventus Medical, a privately-held medical device company focused on improving the lives of patients with sleep-disordered breathing, today announced that the company's PROVENT(R) Sleep Apnea Therapy received the Runners-Up Award in The Wall Street Journal 2009 Technology Innovation Awards, Medical Devices category. The results were published in the September 14, 2009 edition of The Wall Street Journal.

(Logo:http://www.newscom.com/cgi-bin/prnh/20090409/SF96872LOGO)

"We are excited to be recognized by The Wall Street Journal for our PROVENT Sleep Apnea Therapy," said John McCutcheon, President and Chief Executive Officer at Ventus Medical. "We are proud of this innovative treatment and the potential benefit it brings to the more than 50 million Americans who have obstructive sleep apnea and those not satisfied with standard therapies. We continue our commitment to developing innovative solutions for people affected by sleep-disordered breathing."

According to The Wall Street Journal, winners were selected from nearly 500 nominations across numerous categories from nearly 20 countries. Of those, more than 180 nominations cleared preliminary screening and were passed on for review by a panel of judges comprised of research institutions, venture capital firms and other companies. Judges evaluated whether innovations were truly groundbreaking and also looked at whether their application would be particularly useful in a time of economic hardship. Only seven percent of entries screened by the judges received an award.

About PROVENT Therapy

PROVENT Therapy is a prescription device indicated for the treatment of obstructive sleep apnea (OSA). It is an easy to use and disposable treatment that works across mild, moderate, and severe OSA. The treatment utilizes nasal expiratory positive airway pressure and has been clinically shown to reduce sleep apnea. It incorporates a novel MicroValve design that is placed over the nostrils and secured with hypoallergenic adhesive. During inhalation, the valve opens allowing nearly unobstructed airflow, and during exhalation, the valve closes, limiting airflow through two small openings, which increases expiratory pressure, helping to keep the airway open.

Currently, PROVENT Therapy is available in limited locations in the United States with the assistance and support of professional sleep physicians. PROVENT Therapy may not be appropriate for everyone. For more information, please visit www.ProventTherapy.com.

Sleep-Disordered Breathing

Sleep-disordered breathing broadly refers to a group of disorders characterized by abnormalities of breathing pattern (such as stopping breathing) or the abnormal reduction in the volume of breaths while sleeping. OSA is the most common type of sleep-disordered breathing. An estimated 50 million people in the United States suffer from OSA, which occurs when the upper airway (near the back of the mouth) collapses during sleep, obstructing the airway and preventing air from entering the lungs. OSA is caused by multiple factors, including sleep-induced relaxation of the throat muscles and tongue, enlarged tonsils and adenoids, an abnormally small airway diameter in the back of the mouth and throat, and extra soft tissue in and around the throat due to being overweight.

About Ventus Medical

Ventus Medical is a medical device company focused on improving the lives of patients with sleep-disordered breathing. Located in Belmont, California, Ventus Medical has developed and markets PROVENT Therapy, an innovative, clinically-proven treatment for OSA. Existing OSA solutions do not always meet patients' needs. Through truly innovative technology, solid clinical evidence, and a focus on the patient, Ventus Medical seeks to deliver consumer-preferred, physician-recommended solutions. The company is privately-held and funded by De Novo Ventures, Mohr Davidow Ventures, and Johnson & Johnson Development Corporation.


'/>"/>
SOURCE Ventus Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rochester Medical Announces New Opportunity in the United Kingdom
2. Webmedx Launches New Data-Mining Solution for Medical Transcription and Speech-Generated Documents
3. Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
4. FDA Awards Three Grants Designed to Stimulate Development of Pediatric Medical Devices
5. Adnan H. Tahir, M.D., Named Chief Medical Officer of Sisters of Charity Health System
6. GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care
7. Alere Executive Keynote at DMAA Conference Stresses Combining Medical and Health Improvement Models to Bring About Cost-Effective Changes in Healthcare Reform
8. PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009
9. Motorolas 802.11n Wireless LAN Solution Improves Patient Care and Wireless Security at Memorial Medical Center of Western Michigan
10. Winner Medical Solely Sponsored the 2009 China Medical Textile Industry Forum
11. ATS Medical Announces Implant Milestone for the ATS 3f Aortic Bioprosthesis Achieved at Columbia University Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... 2017 , ... Accreditation Commission for Health Care (ACHC) is ... (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s Home ... University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. , ...
(Date:4/28/2017)... Clara, CA (PRWEB) , ... April 28, 2017 ... ... is pleased to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep ... user experience, since it streamlines the reporting process and provides a familiar interface ...
(Date:4/28/2017)... ... ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today that ... as “stable.” At the same time, the ratings agency cautioned that the company’s rating ... “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to being ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, ... the GlycoMark test throughout the Northeast U.S. , GlycoMark is the only ... The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic ...
(Date:4/28/2017)... ... 2017 , ... Ushio America proudly introduces the new ... solution for F32T8 fluorescent lamps on most instant-start and programmed-start electronic ballasts so ... lamps utilize the existing electronic ballast, saving labor and maintenance costs. It’s easy ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... , April 20, 2017 Eyevensys, ... the first non-viral gene expression technology that enables the ... eye to address a wide range of ophthalmic diseases, ... and Healthcare products Regulatory Agency (MHRA) to advance its ... ...
(Date:4/19/2017)... - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that ... Conference 2017 at the Sheraton Hotel in Toronto, Ontario ... of the Company is scheduled to present on Tuesday, May 2 ... the Chairman of the Board, Tony Holler will also ... For more ...
Breaking Medicine Technology: